- Home
- ADSE vs ATXS Comparison
ADSE vs ATXS Comparison
Compare ADSE & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADSE
- ATXS
- Stock Information
- Founded
- ADSE 1980
- ATXS 2008
- Country
- ADSE Ireland
- ATXS United States
- Employees
- ADSE N/A
- ATXS N/A
- Industry
- ADSE Industrial Specialties
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- ADSE Consumer Discretionary
- ATXS Health Care
- Exchange
- ADSE Nasdaq
- ATXS Nasdaq
- Market Cap
- ADSE 728.1M
- ATXS 669.8M
- IPO Year
- ADSE N/A
- ATXS 2015
- Fundamental
- Price
- ADSE $13.24
- ATXS $9.37
- Analyst Decision
- ADSE Hold
- ATXS Strong Buy
- Analyst Count
- ADSE 1
- ATXS 5
- Target Price
- ADSE $14.00
- ATXS $25.60
- AVG Volume (30 Days)
- ADSE 93.5K
- ATXS 219.2K
- Earning Date
- ADSE 09-12-2024
- ATXS 11-13-2024
- Dividend Yield
- ADSE N/A
- ATXS N/A
- EPS Growth
- ADSE N/A
- ATXS N/A
- EPS
- ADSE N/A
- ATXS N/A
- Revenue
- ADSE $158,974,606.00
- ATXS N/A
- Revenue This Year
- ADSE $98.67
- ATXS N/A
- Revenue Next Year
- ADSE $47.66
- ATXS N/A
- P/E Ratio
- ADSE N/A
- ATXS N/A
- Revenue Growth
- ADSE 168.42
- ATXS N/A
- 52 Week Low
- ADSE $6.10
- ATXS $4.26
- 52 Week High
- ADSE $15.01
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- ADSE 43.56
- ATXS 30.44
- Support Level
- ADSE $13.18
- ATXS $11.40
- Resistance Level
- ADSE $14.33
- ATXS $11.75
- Average True Range (ATR)
- ADSE 0.70
- ATXS 0.75
- MACD
- ADSE -0.14
- ATXS -0.23
- Stochastic Oscillator
- ADSE 14.58
- ATXS 7.64
About ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services which enable the customer to control and manage the system. Geographically, it derives a majority of its revenue from Europe.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.